F rom the launch of any discussion about complementary and alternative medicine (CAM), we are challenged by the lack of a clear definition. CAM has been defined as "a group of diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine." 1, p 1 Although this is an example of one of the best working definitions of treatments considered CAM or integrative medicine, there are important limitations to the definition. First, the definition lumps together very different agents or interventions, and it is not possible to generalize about the safety and efficacy of these treatments. Second, the definition relies greatly on subjectivity; what is considered conventional or mainstream varies between health care providers and among patients. Third, the definition focuses on what CAM is not, mainly not inside the realm of mainstream treatment, rather than what CAM treatments actually are. Therefore, it was a daunting mission for my colleagues and me on the American Psychiatric Association's Task Force on CAM in psychiatry to select topics on which to focus, as producing a report on CAM in psychiatry was an elusive goal. We chose to focus on selected CAM treatments for major depressive disorder (MDD), and primarily reviewed treatments with enough efficacy and safety data, as well as common use in depression, to produce a clinically relevant report. 2 We sought evidence that is highly valued in Western medicine, data from randomized controlled trials (RCTs). It has been argued that some treatments considered CAM do not lend themselves easily to such study. For example, acupuncture and exercise are treatments in which finding appropriate control conditions is challenging. Also, some treatments are considered to be established treatments in particular contexts or cultures. However, we sought to assess an evidence base for these treatments with the same scrutiny we would apply to a pharmacologic or psychotherapeutic intervention.
Patients often use CAM treatments for psychiatric indications, and it has been documented that they often do not disclose the use of these treatments to their psychiatrists. 3 Epidemiologic studies demonstrate high use of CAM, with up to 40% of adults in the United States using at least one treatment annually, with over $33 billion dollars spent out of pocket each year. 3 CAM treatments may be particularly attractive to patients with psychiatric disorders. Many can be obtained without a prescription or evaluation, in a field of medicine (psychiatry) in which disorders are often highly stigmatized. However, this availability also carries substantial risk. Lack of appropriate diagnosis, evaluation, and monitoring is seriously risky in the course of disorders that are often severe and have high rates of morbidity and even mortality. Also, psychotropics often carry high burdens of side effects and risks, and the idea of a CAM or natural treatment may carry connotations of safety, when safety may not be established. Even in the case of CAM treatments with benign side effect profiles, deferring effective treatment may result in trials of interventions that lack efficacy and have not received adequate study.
In this issue, Dr David Mischoulon and colleagues (see Wu et al 4 ) assess the data pertaining to the role of acupuncture in the treatment of depressive disorders. They systematically reviewed the literature for studies assessing the efficacy of acupuncture as a monotherapy for depression, as an augmentation agent and as a means by which to alleviate side effects of medication management of depression. The context and application of acupuncture historically has been different than that of drug development, as it has evolved in diagnostic systems that are different than Western medicine, and acupuncture is often used in parallel with other treatments in Eastern medicine. Wu et al 4 include in their paper a focus on populations that may particularly benefit from nonmedication treatment options for MDD, including pregnant women. As many patients would prefer to be treated without medications or with minimal medications, and insufficient data are available for acupuncture in the treatment of depressive disorders, more high-quality systematic RCTs would serve to elucidate its role in the treatment of MDD.
Also in this issue, Dr George I Papakostas and colleagues 5 discuss the role of folate, S-adenosylmethionine (SAMe), and related compounds in the 1-carbon cycle and depression. The authors explain the rationale for considering these compounds in the treatment of depression, and their role in the production of neurotransmitters known to be important in mood regulation. Use of nutritional supplements for the treatment of psychiatric disorders is an exciting area of study, as these supplements are generally well tolerated and well accepted by patients. Notably, SAMe is one of the nutritional supplements most rigorously studied for the treatment of depression, primarily studied as a monotherapy, and demonstrated in many studies to have efficacy, compared with placebo, and similar efficacy to standard antidepressants. Currently, data do not support the use of folate as a monotherapy for MDD, but it is a reasonable addition to a treatment plan for MDD, particularly in reproductive-aged women, as it is known to reduce the risk of birth defects.
The one-carbon cycle compounds reviewed in this issue are only one example of nutritional factors with growing evidence for a role in depression. To date, evidence supports a relation between nutrition and mood disorders, with the greatest amount of study so far in the area of MDD. Depression and obesity appear to have an important association, 6 and population studies demonstrate that different patterns of food intake may have variable rates of risk of depression, with more processed foods in the diet noted as a risk factor. [7] [8] [9] Where does this leave us? Mental health care providers should open the door for discussions with patients about CAM treatments and nutrition, educating patients that natural does not always mean safe, and recommending that any treatment is carefully monitored with the same scrutiny as a standard medication trial. If we have a collaborative, open, and scientifically rigorous view of CAM treatments, we allow patients to have trials of appropriate treatments in the setting of a carefully monitored therapeutic relationship.
